Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | GMNN | O75496 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | BLM | P54132 | 3/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetylcarnitine SCHEMBL13323920 | 1.00 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL7079427 | 1.00 | LMNA (0.96) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2639482 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL28744378 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL4749513 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL3004012 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL2515409 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL29376874 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL20721036 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A | |
| Acetylcarnitine SCHEMBL27571008 | 0.98 | LMNA (0.93) | LMNASMN1; SMN2CYP1A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667007-A2 | NOVEL ASSOCIATION OF GASTRODIA ELATA AND VITAMIN B | Futura S.r.l. (IT) | 2025-12-24 | — | — | EP | disclosed |
| EP-4663194-A2 | NOVEL ASSOCIATION OF ACTIVE INGREDIENTS, PHARMACEUTICAL AND/OR NUTRACEUTICAL COMPOSITIONS CONTAINING IT AND THEIR USE IN THE PREVENTION AND REPAIR OF DAMAGE TO THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM | Futura S.r.l. (IT) | 2025-12-17 | — | — | EP | disclosed |
| EP-4647078-A2 | NOVEL ASSOCIATION OF GASTRODIA ELATA, CITICOLINE, L-ACETYLCARNITINE AND VITAMIN B | Futura S.r.l. (IT) | 2025-11-12 | — | — | EP | disclosed |
| EP-4482988-B1 | PROCESS FOR LIMING OF HIDES, SKINS OR PELTS | STAHL INT B V (NL) | 2025-11-05 | — | — | EP | disclosed |
| EP-4643864-A2 | NOVEL ASSOCIATION OF GASTRODIA ELATA, CITICOLINE, L-ACETYLCARNITINE, VITAMIN B AND VITAMIN D | Futura S.r.l. (IT) | 2025-11-05 | — | — | EP | disclosed |
| EP-4640222-A2 | NOVEL ASSOCIATION OF GASTRODIA ELATA, CITICOLINE, L-ACETYLCARNITINE AND VITAMIN D | Futura S.r.l. (IT) | 2025-10-29 | — | — | EP | disclosed |
| EP-4631508-A2 | NOVEL ASSOCIATION OF GASTRODIA ELATA AND VITAMIN D | Futura S.r.l. (IT) | 2025-10-15 | — | — | EP | disclosed |
| EP-4626452-A1 | NOVEL ASSOCIATION OF ACTIVE INGREDIENTS, PHARMACEUTICAL AND/OR NUTRACEUTICAL COMPOSITIONS CONTAINING IT AND THEIR USE IN THE PREVENTION AND REPAIR OF DAMAGE TO THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM | Futura S.r.l. (IT) | 2025-10-08 | — | — | EP | disclosed |
| US-20250188551-A1 | PROCESS FOR LIMING OF HIDES, SKINS OR PELTS | STAHL INTERNATIONAL B.V. (NL) | 2025-06-12 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-1453791-B1 | ACETYL L-CARNITINE SALT WITH A DICARBOXILIC ORGANIC ACID AND PROCESS FOR PREPARING SAME | SIGMA TAU IND FARMACEUTI (IT) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009077173-A2 | DNA-ENCODED CHEMICAL LIBRARIES | PHILOCHEM AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090137670-A1 | Amino Acid Compounds | THERMOLIFE INTERNATIONAL, LLC | 2009-05-28 | — | — | US | disclosed |
| WO-2009027388-A2 | IMAGING MEDIUM COMPRISING HYPERPOLARISED 13C-ACETATE AND USE THEREOF | GE HEALTHCARE LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
| EP-1453791-A1 | ACETYL L-CARNITINE SALT WITH A DICARBOXILIC ORGANIC ACID AND PROCESS FOR PREPARING SAME | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-09-08 | — | — | EP | disclosed |
| US-6673837-B2 | SOLID, CRYSTALLINE, NON-HYGROSCOPIC ACETYL L-CARNITINE FUMARATE; BOILING POINT 0F 105-110 DEGREES C | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-01-06 | — | — | US | disclosed |
| WO-2003053911-A1 | ACETYL L-CARNITINE SALT WITH A DICARBOXILIC ORGANIC ACID AND PROCESS FOR PREPARING SAME | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-03 | — | — | WO | disclosed |
| US-20030119904-A1 | Acetyl L-carnitine salt with a dicarboxilic organic acid and process for preparing same | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-06-26 | — | — | US | disclosed |
| US-4721728-A | ANTILIPEMIC AGENTS, METABOLISM | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.P.A. (IT) | 1988-01-26 | — | — | US | disclosed |
| EP-0220538-A1 | New pantothenyl derivatives | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137670-A1 | Amino Acid Compounds | OAT, CRAT, SLC25A20 | LMNA 1764/4885SMN1; SMN2 736/4885CYP1A2 1272/4885 |
| US-20030119904-A1 | Acetyl L-carnitine salt with a dicarboxilic organic acid and process for preparing same | CRAT, SLC25A20, CPT2 | LMNA 774/4885SMN1; SMN2 2377/4885CYP1A2 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.